Duchenne News Tags: Sarepta

Sarepta Therapeutics Announces Advisory Committee Meeting Will Be Held for SRP-9001

Sarepta announces advisory meeting for SRP-9001, an investigational gene therapy for the treatment of Duchenne muscular dystrophy.

February 28, 2023

Sarepta Therapeutics Announces Call for Applications for the 6th Annual Route 79, The Duchenne Scholarship Program

Sarepta announces official release of 2023-2024 Route 79 Duchenne Scholarship Program

November 28, 2022

Sarepta Announces U.S. FDA Accepts Filing and Granted Priority Review for the Biologics License Application for SRP-9001

Sarepta announces FDA filing and priority review for biologics license application for SRP-9001

September 29, 2022

Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy

Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy.

September 13, 2022

Sarepta Shares EMBARK (SRP-9001-301) Study Enrollment Update

On September 13, 2022, Sarepta Therapeutics shared an update announcing that their EMBARK (SRP-9001-301) study is fully enrolled.

September 7, 2022

Sarepta Announces Recipients of Route 79, Duchenne Scholarship Program for 2022-2023

On Sept. 7, 2022, Sarepta Therapeutics announced the recipients for its Route 79, Duchenne Scholarship Program for the 2022-2023 academic year.

September 6, 2022

Sarepta Announces That FDA Has Lifted Clinical Hold on SRP-5051

On Sept. 6, 2022, Sarepta Therapeutics announced that the Food and Drug Administration lifted its clinical hold on SRP-5051 for the treatment of Duchenne muscular dystrophy.

July 6, 2022

Sarepta Therapeutics Shares Functional Improvements of Investigational Gene Therapy SRP-9001

On July 6, 2022, Sarepta Therapeutics shared new functional data across multiple studies from the clinical development program for investigational gene therapy SRP-9001.

June 23, 2022

Sarepta Shares Community Letter Regarding MOMENTUM Trial

On June 23, 2022, Sarepta shared news regarding the MOMENTUM study.

June 9, 2022

Sarepta Addresses Questions about Status of Clinical Trial Programs

On June 9, 2022, Sarepta provided a community update on their actively recruiting clinical trial programs for Duchenne muscular dystrophy.

Jett Foundation, Inc.
65 Cordage Park Circle
Suite 130 | Plymouth, MA 02360
781-585-5566 | info@jettfoundation.org

Sitemap

Support Jett Foundation

Jett Foundation, Inc. is a 501(c)3 registered tax-exempt nonprofit organization. Our Federal Tax ID is 04-3563445.

Programs

Events